Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Multicentric, Parallel Group Therapeutic Equivalence Study Comparing Efficacy, Safety and Immunogenicity of Subcutaneous DMB-3115 and Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT04785326 is registered in ClinicalTrials.gov with Dong-A ST Co., Ltd. as lead sponsor.

NCT NCT04785326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04785326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Multicentric, Parallel Group Therapeutic Equivalence Study Comparing Efficacy, Safety and Immunogenicity of Subcutaneous DMB-3115 and Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Lead sponsor
Dong-A ST Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
April 28, 2021
Completion date
November 16, 2022
Enrollment
598 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe chronic plaque psoriasis